| Ticker: ESTI | 1049 Kiel Court | |
| Exchange: NASDAQ-National Market | Sunnyvale, California 94089 | |
| Industry: Manufacturing | (408) 747-0120 |
| Type of Shares: | Common Shares | Filing Date: | 4/18/96 | |
| U.S. Shares: | 4,000,000 | Offer Date: | 5/31/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $13.00 - $15.00 | |
| Primary Shares: | 4,000,000 | Offer Price: | $16.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.12 | |
| Offering Amount: | $56,000,000 | Selling: | $0.65 | |
| Expenses: | $1,100,000 | Reallowance: | $0.10 | |
| Shares Out After: | 15,682,396 |
| Manager | Tier | Phone |
| PaineWebber Incorporated | Lead Manager | (212) 713-2626 |
| Deutsche Morgan Grenfell | Co-manager | (212) 468-5000 |
| Jefferies & Company Incorporated | Co-manager | (800) 933-6656 |
| Auditor: Coopers & Lybrand | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $2.71 | $1.75 | $0.53 | Assets: | $4.68 |
| Net Income: | -$2.43 | $0.08 | -$0.66 | Liabilities: | $3.96 |
| EPS: | -$0.19 | $0.01 | -$0.05 | Equity: | $0.72 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company designs, develops, manufactures and distributes laser-based surgical products and disposable fiber-optic accessories for the treatment of advanced cardiovascular disease through transmyocardial revascularization (TMR). TMR is a surgical procedure performed on the beating heart in which a laser device is used to create pathways through the myocardium, or heart muscle, directly into the heart chamber. The pathways are intended to enable improved blood supply to the myocardium from the heart chamber. TMR potentially offers end-stage cardiac patients a means to alleviate their symptoms of angina, or chest pain, and improve their quality of life. The company currently offers its Eclipse TMR 2000 laser system for sale in limited numbers for investigational use only, pursuant to an Investigational Device Exemption (IDE) granted by the U.S. Food and Drug Administration in September 1995. The company initial clinical study, which commenced in November 1995, is designed to assess the safety and effectiveness of the company's TMR procedure as compared with drug therapy in patients with severe angina. Phase I of this clinical study was completed in January 1996, and Phase II, the final phase of the clinical trial, commenced in March 1996. |
| Use of Proceeds |
| Proceeds from the proposed offering will be used for research and development including clinical trials; expansion of sales and marketing resources; capital expenditures, including expansion of manufacturing facilities; repayment of outstanding indebtedness and overdue obligations; and general corporate purposes including working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.